| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Insulin-dependent diabetes mellitus (IDDM) during puberty is associated with a reduction in circulating concentrations of insulin-like growth factor-I (IGF-I) and low IGF bioactivity. Altered levels of the IGF-binding proteins (IGFBPs), including low IGFBP-3 and elevated IGFBP-1, have also been described. These abnormalities have been linked to poor growth and deteriorating blood glucose control. We have therefore examined the effects of recombinant human IGF-I (rhIGF-I) administration on the levels of IGF-I, IGF-II, IGFBP-1, IGFBP-3 and IGF bioactivity in a group of 9 late-pubertal adolescents with IDDM.
This was a double-blind placebo controlled study with each individual admitted on two occasions when either rhIGF-I (40 µg/kg) or placebo was administered by subcutaneous injection in the thigh at 1800 h. Blood samples were then taken for the subsequent 22 h. The half-life of administered rhIGF-I (12·1–22·2 h) was similar to that previously described in normal subjects. There was a small increase in IGFBP-3 concentrations overnight following rhIGF-I administration when compared to placebo, whereas the levels of IGF-II decreased. Under strict euglycaemic conditions, the relationship between insulin and IGFBP-I did not appear to be affected by rhIGF-I administration although the levels of IGFBP-1 tended to be higher overnight. IGF bioactivity was low during the placebo study, and although within the normal adult range following administration of IGF-I, was still relatively low for adolescents in late puberty. Gel filtration chromatography revealed an increase in the fractions corresponding to the 150 kDa complex throughout the duration of the study and to a lesser extent the fractions corresponding to free IGF-I which reached a maximum of 7% of total IGF-I levels. In conclusion, the subcutaneous administration of rhIGF-I in a dose of 40 pg/kg to a group of adolescents with IDDM led to a sustained increase in IGF-I levels and a rise in IGF bioactivity despite a fall in IGF-II and a trend towards higher IGFBP-1 concentrations.
Journal of Endocrinology (1994) 142, 367–374
This article has been cited by other articles:
|
|
 |
|
  T. Saukkonen, R. Amin, R. M. Williams, C. Fox, K. C. Yuen, M. A. White, A. M. Umpleby, C. L. Acerini, and D. B. Dunger Dose-Dependent Effects of Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF Binding Protein-3 Complex on Overnight Growth Hormone Secretion and Insulin Sensitivity in Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4634 - 4641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Simpson, N. C. Jackson, F. Shojaee-Moradie, R. H. Jones, D. L. Russell-Jones, P. H. Sonksen, D. B. Dunger, and A. M. Umpleby Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Crowne, J. S. Samra, T. Cheetham, C. L. Acerini, A. Watts, J. M. P. Holly, and D. B. Dunger The Role of IGF-Binding Proteins in Mediating the Effects of Recombinant Human IGF-I on Insulin Requirements in Type 1 Diabetes Mellitus J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3686 - 3691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.P. Holmes, J.M.P. Holly, and P.W. Soothill Maternal serum insulin-like growth factor binding protein-2 and -3 and fetal growth Hum. Reprod., July 1, 1999; 14(7): 1879 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Allen, C. A. Bloor, R. A. Knight, and M. A. Spiteri Expression of Insulin-like Growth Factor Binding Proteins in Bronchoalveolar Lavage Fluid of Patients with Pulmonary Sarcoidosis Am. J. Respir. Cell Mol. Biol., August 1, 1998; 19(2): 250 - 258. [Abstract] [Full Text]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
